Here we report the cloning and functional characterization of the cyclin D-dependent kinase 4 and 6 (Cdk4/6) inhibitory protein Cdkn2d/p19 of (-Ink4d). - is the only family gene highly expressed during development and its transcripts were detected maternally and during neurulation. The -Ink4d protein has 63% identity to mouse and human Cdkn2d/p19 and its function as a negative regulator of cell cycle traverse is evolutionary conserved. Indeed, -lnk4d can functionally substitute for mouse Cdkn2d in binding to mouse Cdk4 and inhibiting cyclin-D1-dependent CDK4 kinase activity. Further, enforced expression of -lnk4d arrests mouse fibroblasts in the G1 phase of the cell cycle. These findings indicate that CDKN2d/p19 is conserved through vertebrate evolution and suggest -lnk4d may contribute to the development of .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192657 | PMC |
| http://dx.doi.org/10.4172/2168-9296.1000133 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Three sample preparation methods for clinical determination of CDK4/6 inhibitors with endocrine therapy in breast cancer patient plasma using LC-MS: Cross-validation (red), ecological (green) and economical (blue) assessment.
J Pharm Biomed Anal
November 2024
University of Zagreb Faculty of Pharmacy and Biochemistry, Department of Pharmaceutical Analysis, Ante Kovačića 1, Zagreb, Croatia. Electronic address:
Article Synopsis
- Cyclin D-dependent kinase 4/6 inhibitors, along with aromatase inhibitors and estrogen receptor degraders, are being evaluated for their effectiveness in therapeutic drug monitoring due to a lack of routine clinical methods.
- This study assesses three sample preparation techniques: dispersive liquid-liquid microextraction (DLLME), solid-phase extraction (SPE), and phospholipid removal (PLR), for accurately measuring these drugs in patient plasma.
- Results show that all methods are highly precise and accurate, with DLLME being the most eco-friendly, PLR allowing for high throughput, and SPE offering superior analytical performance, enabling users to choose the best method based on their needs.
Case report: a rare clinical presentation of a difficult diagnosis of dedifferentiated liposarcoma showing leiomyosarcoma phenotype in the ileocecal region.
Front Oncol
November 2024
Department of Orthopedic Surgery, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Japan.
Dedifferentiated liposarcoma is a malignant lipomatous tumor that rarely occurs in the gastrointestinal tract, including the ileocecal region. In this case, computed tomography and magnetic resonance imaging showed no fatty mass located in the mesenteric or submucosal lesion, and positron emission tomography-computed tomography showed a high maximum standardized uptake value, collectively indicating the gastrointestinal stroma tumor and lymphoma. The pathological findings resemble leiomyosarcoma; the immunohistochemistry findings including mouse double minute 2 homolog and cyclin D-dependent kinase-4 and amplification of mouse double minute 2 homolog in fluorescence hybridization just favored the diagnosis of dedifferentiated liposarcoma with leiomyosarcoma phenotype and not leiomyosarcoma.
View Article and Find Full Text PDFPropofol Modulates Gallbladder Cancer Progression via miR-4430/SLC19A3 Axis.
Altern Ther Health Med
October 2024
Background/aim: Propofol is a common anesthetic used during surgery. MircoRNA (miRNA), especially miR-4430, is currently a research hotspot in GBC. This study investigates whether propofol regulates GBC through the miR-4430/SLC19A3 axis.
View Article and Find Full Text PDFOptimisation of dispersive liquid-liquid microextraction for plasma sample preparation in bioanalysis of CDK4/6 inhibitors in therapeutic combinations for breast cancer treatment.
Heliyon
August 2023
University of Zagreb Faculty of Pharmacy and Biochemistry, Department of Pharmaceutical Analysis, Zagreb, Croatia.
Cyclin D dependent kinase 4 and 6 (CDK 4/6) inhibitors are novel anticancer drugs used in therapeutic combinations with endocrine therapy for breast cancer treatment. Their determination in patient plasma is of high interest as a prerequisite for possible therapeutic drug monitoring. Dispersive liquid-liquid microextraction (DLLME) shows great potential in bioanalytical sample preparation.
View Article and Find Full Text PDFEmerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer.
Biology (Basel)
May 2023
The Centre for Biomedical and Chemical Sciences, School of Science, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland 1010, New Zealand.
Breast cancer is now the most common cancer worldwide, and it is also the main cause of cancer-related death in women. Survival rates for female breast cancer have significantly improved due to early diagnosis and better treatment. Nevertheless, for patients with advanced or metastatic breast cancer, the survival rate is still low, reflecting a need for the development of new therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!